title: Treating osteoporosis with teriparatide: many unknowns?
abstract: In the US, teriparatide is indicated for the treatment of patients with osteoporosis who are "at high risk for fracture." Although placebo-controlled trials show that teriparatide can reduce fractures, there is little information on its efficacy compared to available alternatives. In the US, the Food and Drug Administration highlighted concerns about teriparatide's carcinogenic effects in rats. Company-sponsored studies have been voluntarily stopped.
authors: Vijay K
authors: VK
authors: Shukla
mesh_terms: D000328:Adult; D019386:Alendronate / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D015519:Bone Density / Q000187:drug effects; D002170:Canada; D017326:Clinical Trials, Phase III as Topic; D016527:Drug Costs; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D012307:Risk Factors; D019379:Teriparatide / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D019379:Teriparatide; D019386:Alendronate